Gyre Therapeutics (GYRE) Receivables (2012 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Receivables of $26.8 million for Q1 2026, up 29.22% year-over-year from $20.7 million in Q1 2025, and down 14.7% quarter-over-quarter from $31.4 million in Q4 2025.
Gyre Therapeutics (GYRE) Receivables (2012 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Receivables for 15 consecutive years, with $26.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables rose 29.22% year-over-year to $26.8 million; the TTM figure through Mar 2026 stood at $26.8 million (up 29.22% YoY), while the FY2025 annual figure was $36.9 million, up 49.1% from the prior year.
- Receivables declined to $26.8 million in Q1 2026 per GYRE's latest filing, from $31.4 million in the prior quarter.
- Across five years, Receivables topped out at $31.4 million in Q4 2025 and bottomed at $564000.0 in Q1 2022.
- Historically, Receivables has averaged $17.3 million across 5 years, with a median of $19.9 million in 2024.
- On a YoY basis, Receivables climbed as much as 842.57% in 2022 and fell as far as 43.94% in 2022.
- Gyre Therapeutics' Receivables stood at $17.1 million in 2022, then declined by 17.96% to $14.1 million in 2023, then jumped by 76.11% to $24.8 million in 2024, then increased by 26.94% to $31.4 million in 2025, then slipped by 14.7% to $26.8 million in 2026.
- Business Quant data shows GYRE's Receivables at $26.8 million in Q1 2026, $31.4 million in Q4 2025, and $26.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 28.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.33 Mn |
| Mar 31, 2026 | 26.81 Mn |
| Dec 31, 2025 | 31.43 Mn |
| Sep 30, 2025 | 26.26 Mn |
| Jun 30, 2025 | 25.06 Mn |
| Mar 31, 2025 | 20.75 Mn |
| Dec 31, 2024 | 24.76 Mn |
| Sep 30, 2024 | 20.34 Mn |
| Jun 30, 2024 | 19.92 Mn |
| Mar 31, 2024 | 16.75 Mn |
| Dec 31, 2023 | 14.06 Mn |
| Mar 31, 2023 | 5.00 Mn |
| Dec 31, 2022 | 17.14 Mn |
| Sep 30, 2022 | 5.00 Mn |
| Jun 30, 2022 | 5.00 Mn |
| Mar 31, 2022 | 564,000.00 |
| Dec 31, 2021 | 1.82 Mn |
| Sep 30, 2021 | 1.11 Mn |
| Jun 30, 2021 | 1.97 Mn |
| Mar 31, 2021 | 1.01 Mn |